about
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured ratsThe role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy.Rare variants in genes encoding MuRF1 and MuRF2 are modifiers of hypertrophic cardiomyopathy.Female sex is associated with worse prognosis in patients with hypertrophic cardiomyopathy in China.SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathyFunctional effects of the TMEM43 Ser358Leu mutation in the pathogenesis of arrhythmogenic right ventricular cardiomyopathyLamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease.Autosomal recessive transmission of MYBPC3 mutation results in malignant phenotype of hypertrophic cardiomyopathy.Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium DesensitizationHigh mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis.E2F3 plays an essential role in cardiac development and function.Activation of cardiac hypertrophic signaling pathways in a transgenic mouse with the human PRKAG2 Thr400Asn mutation.Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy.Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle.Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension.Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23.Somatic mutations in pulmonary arterial hypertension: primary or secondary events?A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemiaFunctional role of AMP-activated protein kinase in the heart during exerciseCharacterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosusVanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes. Evidence for transduction of amplitude of signaling into duration of responseHuman eHAND, but not dHAND, is down-regulated in cardiomyopathiesIncreased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathyMidterm outcomes of off-pump and on-pump coronary artery revascularization in renal transplant recipientsMalignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy
P50
Q28594348-F0DBBFBD-0BB8-41E5-88BA-D56A007EBD65Q28730633-1C5A6577-A973-4ED3-BC5F-C8131716AAAEQ33350170-10F635FB-0999-4680-B887-CA540F366572Q33907456-C0A2E2E9-C1EF-468C-ABE4-2AD50088C440Q33927715-4E4F98A6-96A4-46D6-A5AD-C4F9D3A7B924Q34101200-7C209C4D-C31C-4C93-A9FB-7266CCC93256Q34212672-F4531ED5-A837-4FDA-AB02-10C211DC56E0Q34446739-B157F90F-78E4-4A2E-AE63-FEFC0173CDFFQ34806455-0452E172-FEF7-4B7A-B7C3-CDCC8CA281C4Q35026241-00C9E6DF-9630-447C-967C-EC8340CB8606Q36217967-BB3867E7-DFAD-4022-BFF2-52B29F19B355Q36621780-2F9393C6-8E19-4DAC-A3D4-756C141669FDQ39741074-BD2C7281-CC33-4708-BC9E-E486AF0DCC63Q42016691-7770D6A2-7AB9-45A7-8106-417C3D4009BCQ43224228-1975401A-0D5B-44B8-948F-669FBE4766B5Q44553658-F2752AD7-CD0E-41A3-A3E7-322280282FE9Q47755014-427FAE62-8B06-45A0-ADB5-9F16039BFB56Q47866453-B1D1EF3E-36DE-4D55-ABF4-B60F24F526EFQ52610998-B7866CBF-231E-4A45-8261-4FC96209F6C7Q54284047-ED4E7858-E314-4BC0-AFE2-39AB8CEFE25DQ54636361-0D61BECE-66FF-4B13-A8DB-3C50D4203D3FQ59607753-2142715D-458C-4B99-A9C9-C936112A5C05Q59607761-6169C8ED-825D-4910-B133-C4185662266CQ71127561-AC199535-CE03-4CC5-8BA8-05356BB1725DQ71610691-A43D2625-5FB2-4457-B98B-28CD2CA5C9D5Q74493520-70B900A8-5FFB-4567-9E20-40E20E1409ACQ81454945-78C6F828-CFEC-40B2-A7E3-C80B45D3644AQ85088305-D6F8D0DF-6363-421B-AAA2-6845DDF045B2Q87602989-DE361232-06D5-48D4-B5DF-345BDC730607
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ferhaan Ahmad
@ast
Ferhaan Ahmad
@en
Ferhaan Ahmad
@es
Ferhaan Ahmad
@nl
type
label
Ferhaan Ahmad
@ast
Ferhaan Ahmad
@en
Ferhaan Ahmad
@es
Ferhaan Ahmad
@nl
prefLabel
Ferhaan Ahmad
@ast
Ferhaan Ahmad
@en
Ferhaan Ahmad
@es
Ferhaan Ahmad
@nl
P106
P1153
7101862128
P31
P496
0000-0003-2877-4641